Form 8-K - Current report:
SEC Accession No. 0001193125-25-121310
Filing Date
2025-05-16
Accepted
2025-05-16 08:06:10
Documents
18
Period of Report
2025-05-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d916136d8k.htm   iXBRL 8-K 58862
2 EX-2.1 d916136dex21.htm EX-2.1 468212
3 EX-10.1 d916136dex101.htm EX-10.1 79645
4 EX-99.1 d916136dex991.htm EX-99.1 36377
8 GRAPHIC g916136dsp1a.jpg GRAPHIC 4610
9 GRAPHIC g916136dsp1b.jpg GRAPHIC 4856
  Complete submission text file 0001193125-25-121310.txt   943175

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA inzy-20250516.xsd EX-101.SCH 2850
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20250516_lab.xml EX-101.LAB 18737
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20250516_pre.xml EX-101.PRE 11707
20 EXTRACTED XBRL INSTANCE DOCUMENT d916136d8k_htm.xml XML 3762
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 25956988
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)